Outlook Therapeutics, Inc. - Common Stock (NQ:OTLK)

0.5133 -0.0060 (-1.16%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Outlook Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 22, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

May 22, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

Top 3 Health Care Stocks That Could Blast Off This Month ↗

January 06, 2025

Via Benzinga

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug ↗

January 16, 2025

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

Via Benzinga

This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

December 02, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 27, 2024

Via Benzinga

Nasdaq Down Over 100 Points; HP Shares Plunge ↗

November 27, 2024

Via Benzinga

Dow Falls Over 100 Points; US Crude Oil Stocks Decline ↗

November 27, 2024

Via Benzinga

Topics Stocks

US Stocks Mixed; Economy Grows By 2.8% In Q3 ↗

November 27, 2024

Via Benzinga

Topics Economy

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? ↗

November 27, 2024

Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile.

Via Benzinga

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 11, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 03, 2024

Via Benzinga

OTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024 ↗

August 14, 2024

OTLK stock results show that Outlook Therapeutics beat analyst estimates for earnings per share the third quarter of 2024.

Via InvestorPlace

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

July 11, 2024

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Via MarketBeat

3 Undervalued Gems Set to Soar 1,000% by 2026 ↗

June 25, 2024

Discover the fundamentals behind three undervalued stocks to buy in the oil and gas, advertising, and biotechnology industries.

Via InvestorPlace

MarketBeat Week in Review – 6/17 - 6/21

June 22, 2024

Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally

Via MarketBeat

Topics Economy Stocks

Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside

June 19, 2024

Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target.

Via MarketBeat

OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024 ↗

May 15, 2024

OTLK stock results show that Outlook Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗

April 15, 2024

With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.

Via InvestorPlace

Insiders Buying Outlook Therapeutics And 2 Other Stocks ↗

April 01, 2024

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

Via Benzinga

Gold Moves Lower; Lululemon Shares Plummet ↗

March 22, 2024

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&P 500...

Via Benzinga

Topics Stocks

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 22, 2024

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 22, 2024

Via Benzinga

Dow Dips 200 Points; Nike Shares Fall After Q3 Results ↗

March 22, 2024

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0.54% to 39,565.50 while the NASDAQ rose 0.04% to 16,408.74. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday? ↗

March 22, 2024

Outlook Therapeutics stock sees uptick as European Medicines Agency committee issues positive opinion on ONS-5010/LYTENAVA for wet age-related macular degeneration (wet AMD). Strong trading volume...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 22, 2024

Via Benzinga

Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗

March 12, 2024

The Dow Jones index closed higher by around 47 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

7 of the Best Speculative Stocks You Can Snag for Less Than $1 ↗

March 06, 2024

Although speculative stocks under $1 are by their very nature extremely risky, these ideas might have enough to go the distance.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.